Amphastar Pharmaceuticals, Inc. (AMPH) stock analysis
Healthcare · Drug Manufacturers - Specialty & Generic
From the 10-K filed 2026-02-26
Business type: Franchise
How it makes money
It earns revenue by manufacturing and selling specialized generic and proprietary injectable, inhalation, and nasal prescription pharmaceutical products.
The company focuses on technically challenging dosage forms including solutions, suspensions, metered-dose inhalers, and pre-filled syringes. Its largest revenue generators include BAQSIMI, Primatene MIST, glucagon, epinephrine, and lidocaine. Net revenues were $719.9 million in 2025 and $732.0 million in 2024.
What protects it: the moat
It protects its market position through high technical barriers to entry in complex manufacturing and specialized research capabilities.
Management asserts that specialized capabilities such as characterizing complex molecules, particle engineering, and adhering to strict regulatory standards limit direct competition. However, much of this advantage relies on maintaining complex supply chains and specialized intellectual property without guaranteed exclusivity.
What growth costs
It incurs ongoing costs for research and development, strategic acquisitions, and manufacturing infrastructure investments.
The company invests through internal development of abbreviated new drug applications and biologics license applications, alongside strategic licensing agreements and business acquisitions such as the purchase of BAQSIMI.
What could damage it
A disruption from single-source suppliers or manufacturing partners could immediately impair its ability to supply key products and generate revenue.
Because a significant portion of net revenues relies on a concentrated group of core products, any manufacturing failure, supply chain bottleneck, or loss of a single-source partner for products like BAQSIMI would directly reduce incoming cash flows.
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.